Assessment of Radionuclidic Purity of Sm-153 Produced by Irradiation of Natural Samarium in Tehran Research Reactor (TRR)

Gholipour Peyvandi, R; Salehkoutahi, M; Shirvani Arani, S; Bahrami Samani, A; Ghannadi Maragheh, M

Assessment of Radionuclidic Purity of Sm-153 Produced by Irradiation of Natural Samarium in Tehran Research Reactor (TRR)

Document Type : Research Paper

Authors

R Gholipour Peyvandi

M Salehkoutahi

S Shirvani Arani

A Bahrami Samani

M Ghannadi Maragheh

Abstract

Samarium-153 is one of the most widely used radionuclides in preparation of pain palliation radiopharmaceuticals of bone metastases. Therefore, it is important to realize the types and amount of impurities in the products. The aim of this study is to evaluate the produced impurities (¹⁵⁴Eu, ¹⁵⁵Eu & ¹⁵⁶Eu) both theoretically and experimentally. These impurities are produced in ¹⁵³Sm preparation by irradiation of natural samarium. In the experiment, the gamma spectra are recorded at different time durations, as the half-lives of impurities are longer than ¹⁵³Sm half-life. Moreover, a comparison is also given to show that the results of the experiment and that of theory are in good agreement with each other, where it gives an accurate assessment of the amount and the type of impurities.

Highlights

M.A. Winston, “Radioisotope therapy in bone and joint diseases,” Sem. Nucl. Med. 9: 114-120 (1979).

V.J. Lewington, “Targetted nuclear therapy for bone metastases,” Eur.J.Nucl. Med. 20: 66-74 (1993).

N. Aldo Serafini, “Therapy of metastatic bone pain,” J. Nucl. Med. 42(6): 895-906 (2001).

W.F. Goeckeler, B. Edwards, W.A. Volkert, R.A. Holmes, J. Simon, D. Wilson, “Skeletal localization of ¹⁵³Sm chelates: Potential therapeutic agents,” J. Nucl. Med. 28: 495-504 (1987).

W.A. Volkert, “¹⁵³Sm-chelates: Potential therapeutic radiopharmaceuticals for the treatment of cancer in bone,” Indian J. Nucl. Med. 8: 12-19 (1993).

K.W. Logan, W.A. Volkert, R.A. Holmes, “Radiation dose calculations in persons receiving ingections of ¹⁵³Sm-EDTMP,” J. Nucl. Med. 28: 505-507 (1987).

Neeta Pandit-Taskar, “Radiopharmaceutical therapy for palliation of bone pain from osseous metastases,” J. Nucl. Med. 45: 1358-1365 (2004).

Production logistics and radionuclidic purity aspects of ¹⁵³Sm for radionuclide therapy N. RAMAMOORTHY, 1,2,* P. SARASWATHY,1 M.K. DAS,3 K.S. MEHRA1 and M. ANANTHAKRISHNAN2. Received 4 June 2001, in revised form 30 August 2001 and accepted (30 August 2001).

G. Friedlander, J.W. Kenedy, J.M. Miller, “Nuclear and Radiochemistry,” John Wiley & Sons, Inc, New York (1964).

Yen Wang, “CRC Handbook of Radionuclides,” (1986).

Keywords

Radionuclide

Samarium-153

Rradionuclidic Purity

Gamma Spects

Tehran Research Reactor (TRR)

Radioisotopes

Irradiation

Skeletal Diseases

M.A. Winston, “Radioisotope therapy in bone and joint diseases,” Sem. Nucl. Med. 9: 114-120 (1979).

V.J. Lewington, “Targetted nuclear therapy for bone metastases,” Eur.J.Nucl. Med. 20: 66-74 (1993).

N. Aldo Serafini, “Therapy of metastatic bone pain,” J. Nucl. Med. 42(6): 895-906 (2001).

W.F. Goeckeler, B. Edwards, W.A. Volkert, R.A. Holmes, J. Simon, D. Wilson, “Skeletal localization of ¹⁵³Sm chelates: Potential therapeutic agents,” J. Nucl. Med. 28: 495-504 (1987).

W.A. Volkert, “¹⁵³Sm-chelates: Potential therapeutic radiopharmaceuticals for the treatment of cancer in bone,” Indian J. Nucl. Med. 8: 12-19 (1993).

K.W. Logan, W.A. Volkert, R.A. Holmes, “Radiation dose calculations in persons receiving ingections of ¹⁵³Sm-EDTMP,” J. Nucl. Med. 28: 505-507 (1987).

Neeta Pandit-Taskar, “Radiopharmaceutical therapy for palliation of bone pain from osseous metastases,” J. Nucl. Med. 45: 1358-1365 (2004).

Production logistics and radionuclidic purity aspects of ¹⁵³Sm for radionuclide therapy N. RAMAMOORTHY, 1,2,* P. SARASWATHY,1 M.K. DAS,3 K.S. MEHRA1 and M. ANANTHAKRISHNAN2. Received 4 June 2001, in revised form 30 August 2001 and accepted (30 August 2001).